Latest news

Thumbnail image for Alnylam’s RNA therapy Onpattro bags EU nod

Alnylam’s RNA therapy Onpattro bags EU nod

Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.

31st August 2018

Thumbnail image for EU expands use of Amgen’s Blincyto

EU expands use of Amgen’s Blincyto

European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.

30th August 2018

Thumbnail image for Bayer, J&J’s Xarelto fails to hit PhIII targets

Bayer, J&J’s Xarelto fails to hit PhIII targets

Bayer and Johnson & Johnson’s plans to expand the scope of blood thinner Xarelto have hit a setback after the drug failed to hit targets in two studies in venous thromboembolism and heart failure studies.

28th August 2018

Thumbnail image for EU approves first CAR-T therapies

EU approves first CAR-T therapies

European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.

28th August 2018

Previous  --   7 8 9 10 11 12 13 14 15 16   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download